Key result
Thrombosis and platelet activity markers may identify cardiovascular patients at high risk of thromboembolism.
Why the study?
Sensitive methods for measuring in vivo markers of thrombin activity, fibrinolysis, and platelet activity may help identify patients with mitral stenosis, atrial fibrillation, and cardiomyopathy at high risk of thromboembolism.
Answers are grounded in this paper and cite their sources.
Highlights sensitive markers of thrombin, fibrinolysis, and platelet activation in cardiovascular disease, suggesting utility for thromboembolism risk stratification.
Advances in the understanding of the biochemistry of the mechanism of hemostasis have led to the development of sensitive methods for determining levels of markers which reflect thrombin activity (thrombin-antithrombin III complex, fibrinopeptide A, F1 + 2 fragment), active fibrinolysis (D-dimer, plasmin-alpha 2-plasmin inhibitor complex), and platelet activity (platelet factor 4, beta-thromboglobulin) in vivo. Measurement of these markers may be useful in identifying patients with various cardiovascular disorders at high risk of thromboembolism.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (1997) conducted a review in Mitral stenosis, atrial fibrillation, and cardiomyopathy. Biochemical markers of coagulation activation, active fibrinolysis, and platelet activity was evaluated on Risk of thromboembolism. Measuring markers of thrombin activity, active fibrinolysis, and platelet activity may identify patients with cardiovascular disorders at high risk of thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: